Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target
Alimentary Pharmacology & Therapeutics · 2024-11 · 60 (9) · 1176-1199
DOI: 10.1111/apt.18231 ↗At a glance
Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, published online on 2024-10-15. Written by Akhilesh Swaminathan and 5 co-authors. Institution: Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand. Major MEDLINE topics: Severity of Illness Index, Quality of Life, Inflammatory Bowel Diseases. Cited 34 times so far (Crossref); 268 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Inflammatory bowel disease (IBD) follows a heterogenous disease course and predicting a patient's prognosis is challenging. There is a wide burden of illness in IBD and existing tools measure disease activity at a snapshot in time. Comprehensive assessment of IBD severity should incorporate disease activity, prognosis, and the impacts of disease on a patient. This review investigates the concept of disease severity in adults with IBD to highlight key components contributing to this.
Methods
To perform this narrative review, a Medline search was conducted for full‐text articles available at 1st March 2024 using search terms which encompassed disease activity assessment, disease severity, prognosis, natural history of Crohn's disease (CD) and ulcerative colitis (UC), and the burden of IBD.
Results
Current methods of disease assessment in IBD have evolved from a focus on the burden of symptoms to one that includes inflammatory targets, genetic, serological, and proteomic profiles, and assessments of quality‐of‐life (QoL), disability, and psychosocial health. Longitudinal studies of IBD suggest that the burden of illness is driven by disease phenotype, clinical markers of complicated disease course (previous intestinal resection, corticosteroid use, perianal disease in CD, recent hospitalisations in UC), gut inflammation, and the impact of IBD on the patient.
Conclusions
Disease severity in IBD can be difficult to conceptualise due to the multitude of factors that contribute to IBD outcomes. Measurement of IBD severity may better encapsulate the full burden of illness rather than gut inflammation alone at a single timepoint and may be associated with longitudinal outcomes.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
- Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand.
- Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand.
- Department of Gastroenterology, Alfred Health and School of Translational Medicine, Monash University, Australia.
- Department of Gastroenterology, Nancy University Hospital, Vandoevre-les-Nancy, France.
- Department of Gastroenterology, INFINY Institute, FHU-CURE, INSERM NGERE, Nancy University Hospital, Vandoeuvre-les-Nancy, France.
ORCID profiles: Akhilesh Swaminathan, Andrew S Day, Miles P Sparrow, Laurent Peyrin-Biroulet, Richard B Gearry
Cite
APA
Swaminathan, A., Day, A. S., Sparrow, M. P., Peyrin-Biroulet, L., Siegel, C. A., & Gearry, R. B. (2024). Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target. Alimentary Pharmacology & Therapeutics, 60(9), 1176-1199. https://doi.org/10.1111/apt.18231
Vancouver
Swaminathan A, Day AS, Sparrow MP, Peyrin-Biroulet L, Siegel CA, Gearry RB. Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target. Alimentary Pharmacology & Therapeutics. 2024;60(9):1176-1199. doi:10.1111/apt.18231
BibTeX
@article{Swaminathan2024,
author = {Swaminathan, Akhilesh and Day, Andrew S and Sparrow, Miles P and Peyrin-Biroulet, Laurent and Siegel, Corey A and Gearry, Richard B},
title = {Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {9},
pages = {1176--1199},
doi = {10.1111/apt.18231}
}
EUVIMED